Curcuminoids for Metabolic Syndrome: Meta-Analysis Evidences Toward Personalized Prevention and Treatment Management

Abstract

The metabolic syndrome (MS) is a multifactorial syndrome associated with a significant economic burden and healthcare costs. MS management often requires multiple treatments (polydrug) to ameliorate conditions such as diabetes mellitus, insulin resistance, obesity, cardiovascular diseases, hypertension, and non-alcoholic fatty liver disease (NAFLD). However, various therapeutics and possible drug-drug interactions may also increase the risk of MS by altering lipid and glucose metabolism and promoting weight gain. In addition, the medications cause side effects such as nausea, flatulence, bloating, insomnia, restlessness, asthenia, palpitations, cardiac arrhythmias, dizziness, and blurred vision. Therefore, is important to identify and develop new safe and effective agents based on a multi-target approach to treat and manage MS. Natural products, such as curcumin, have multi-modalities to simultaneously target several factors involved in the development of MS. This review discusses the recent preclinical and clinical findings, and up-to-date meta-analysis from Randomized Controlled Trials regarding the effects of curcumin on MS, as well as the metabonomics and a pharma-metabolomics outlook considering curcumin metabolites, the gut microbiome, and environment for a complementary personalized prevention and treatment for MS management.

Mitochondrial Fission as a Therapeutic Target for Metabolic Diseases: Insights into Antioxidant Strategies

“…In human neuroblastoma cells, curcumin was found to increase mitochondrial fusion activity, decrease fission machinery, and enhance biogenesis [ 165 ]. The results of clinical studies have been reviewed recently, and suggest that curcumin may be beneficial in patients with metabolic diseases [ 166 , 167 ].…”

Exploring the Contribution of Curcumin to Cancer Therapy: A Systematic Review of Randomized Controlled Trials

“…Together with curcumin, which is the most abundant polyphenol (~77%), the rhizome of Curcuma longa also contains other phenol-based compounds called curcuminoids, the most important being desmethoxycurcumin (~15%) and bisdemethoxycurcumin (~3%) [3,4]. Considering that curcumin prevails over the other congeners, most of the preclinical literature in this field has explored the effects of the pure compound in several experimental systems, whereas only a few papers have studied the biological properties of curcuminoids [5][6][7][8][9]. Unlike preclinical research, which suggested a beneficial role for curcumin in neurodegenerative, cardiovascular, hematological, and infectious diseases, only a few studies have been carried out to confirm these therapeutic effects in humans [10][11][12].…”